If I Were in My 20s, I'd Buy This Magnificent ETF and Hold It Until Retirement

The article recommends the Invesco QQQ Trust (QQQ), an ETF tracking the Nasdaq-100 index, as an ideal long-term investment for young investors in their 20s. The Nasdaq-100 is heavily weighted toward technology stocks (70%) and has historically outperformed the S&P 500 with a 10.9% compound annual return over 27 years versus 8.6% for the S&P 500. The article highlights how major tech companies in the index have benefited from the AI revolution, with the top 10 holdings delivering over 500% average returns since 2023.

08/02/2026, 4:15 PM • The Motley Fool

XLV vs. IBBQ: Is Broad Healthcare Exposure or Biotech Growth the Better ETF Buy?

XLV, a broad healthcare ETF, offers lower costs (0.08% expense ratio) and higher dividend yield (1.60%) with more stability, while IBBQ, a concentrated biotech ETF, delivered stronger one-year returns (45.52% vs 26.79%) but with significantly higher volatility and drawdown risk. The choice depends on investor risk tolerance and investment objectives.

08/01/2026, 5:11 PM • The Motley Fool

Abbott Laboratories vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

Abbott Laboratories and Johnson & Johnson are compared as healthcare investments for 2026. Abbott trades at lower valuations with expected 13% sales growth but faces litigation risks and slower growth in key products like FreeStyle Libre. Johnson & Johnson offers superior profitability and a robust pharmaceutical pipeline with 28 billion-dollar products, though it faces talc settlement costs and biosimilar competition. Abbott is recommended as the better buy due to stronger expected sales growth and lower valuation metrics.

07/31/2026, 3:29 PM • The Motley Fool

1 Unstoppable Dividend ETF Up 26% in 2026 to Buy and Hold for the Next 20 Years

The Schwab U.S. Dividend Equity ETF (SCHD) has delivered a 26% return year-to-date in 2026, significantly outperforming the S&P 500. The ETF focuses on 100 high-quality dividend-paying companies with at least 10 years of consecutive dividend payments, featuring a low 0.06% expense ratio and 3.3% dividend yield. Its portfolio emphasizes healthcare and consumer staples sectors, making it suitable for long-term buy-and-hold investors seeking stability and passive income.

07/31/2026, 10:18 AM • The Motley Fool

VHT vs. PBE: Which Health Care ETF Is the Better Buy?

The Vanguard Health Care ETF (VHT) offers broad healthcare exposure with a low 0.09% expense ratio and 423 holdings, while the Invesco Biotechnology & Genome ETF (PBE) provides focused biotech exposure with 31 holdings and higher growth potential. PBE delivered a stronger 40.88% one-year return but experienced greater volatility with a 37.84% maximum drawdown, while VHT returned 27.85% with lower risk. VHT suits conservative investors seeking steady, low-cost exposure, while PBE appeals to risk-tolerant investors chasing biotech innovation.

07/30/2026, 9:09 AM • The Motley Fool

Watch Out, Eli Lilly and Novo Nordisk: Amgen's Monthly Weight Loss Drug Has 6 Phase 3 Trials Running -- and It's Coming for Your Patients

Amgen is developing MariTide, a monthly weight loss injection, to compete with Eli Lilly's and Novo Nordisk's weekly GLP-1 drugs. While the monthly dosing offers convenience, MariTide's phase 2 efficacy data don't suggest it will outperform competitors. Eli Lilly and Novo Nordisk are advancing newer therapies including oral and combination drugs, positioning them ahead of Amgen in the competitive weight loss market.

07/29/2026, 7:30 AM • The Motley Fool

Vanguard Health Care ETF Outperforms VanEck Biotech on Returns, Yield, and Fees

Vanguard Health Care ETF (VHT) outperforms VanEck Biotech ETF (BBH) with lower fees (0.09% vs 0.35%), higher dividend yield (1.6% vs 0.5%), and superior 5-year returns ($1,278 vs $1,004 on $1,000 invested). VHT offers broad diversification across 411 healthcare holdings, while BBH provides concentrated biotech exposure with 25 stocks and higher volatility.

07/28/2026, 8:20 AM • The Motley Fool

iShares Global Healthcare ETF vs VanEck Biotech ETF: Which ETF Is Better for Profiting With Healthcare in 2026?

The article compares two healthcare-focused ETFs: iShares Global Healthcare ETF (IXJ) with 110 holdings offering global diversification and lower volatility, versus VanEck Biotech ETF (BBH) with 25 concentrated biotech positions delivering higher short-term returns but greater drawdown risk. IXJ is recommended for its superior long-term performance, geographic diversity, and stability despite BBH's impressive 30.8% one-year return.

07/23/2026, 3:30 PM • The Motley Fool

Molecular Glues Clinical Trial Landscape: 80+ Emerging Competitors, Pipeline Dynamics, and Future Opportunities | DelveInsight

The molecular glues market is experiencing significant growth with over 80 active players developing 90+ pipeline candidates. Key companies including Revolution Medicines, Gluetacs Therapeutics, Captor Therapeutics, and others are advancing promising molecular glue degraders across oncology, immunology, and neurodegenerative diseases. Recent developments include FDA Breakthrough Therapy Designation for Daraxonrasib and multiple clinical trial initiations, positioning molecular glues as a promising therapeutic strategy for previously undruggable proteins.

07/23/2026, 1:00 PM • GlobeNewswire

PD-1 and PD-L1 Inhibitors Clinical Trial Pipeline Analysis Demonstrates 180+ Key Companies on the Horizon Expected to Transform the Oncology Space | DelveInsight

A comprehensive analysis reveals over 180 companies developing 200+ PD-1 and PD-L1 inhibitor drugs across various clinical stages. The report highlights major pharmaceutical players advancing pipeline therapies for multiple cancer indications, with approximately 15+ drugs in late-stage development and 30+ in mid and early stages. Recent developments include FDA breakthrough designations and positive clinical trial results for combination therapies.

07/21/2026, 1:00 PM • GlobeNewswire

Could Pfizer Ultimately Be the Biggest Winner in the $100 Billion Weight-Loss Market?

Pfizer is positioning itself as a contender in the rapidly growing $100 billion weight-loss drug market through its acquisition of Metsera and development of promising GLP-1 candidates like MET-097i, which showed strong efficacy with potential monthly dosing. However, the company faces stiff competition from Eli Lilly and Novo Nordisk, who currently lead the market with more advanced triple agonist drugs. While Pfizer may not dominate the space, it is well-positioned to be a significant player, and the company has other growth drivers including oncology pipeline and a high dividend yield of 6.9%.

07/20/2026, 3:15 AM • The Motley Fool

Clinical Stage Partnering Terms and Agreements in Pharmaceuticals and Biotechnology 2020-2026 | Benchmark More Than 1,800 Biopharma Deals with Various Indexes

ResearchAndMarkets.com released a comprehensive report analyzing over 1,859 clinical-stage pharmaceutical and biotechnology partnership deals announced since 2020. The report provides detailed financial terms, deal structures, contract documents, and insights into negotiation dynamics for clinical-stage drug development collaborations, serving as a benchmarking resource for biopharma dealmakers.

07/17/2026, 6:48 AM • GlobeNewswire

Landmark ECOG-ACRIN ENDURANCE Study Co-Authored by International Myeloma Foundation Leaders Provides Evidence for Optimal Duration of Maintenance Therapy

A phase III randomized trial published in the New England Journal of Medicine found that two years of lenalidomide maintenance therapy provides equivalent overall survival to indefinite treatment for standard-risk multiple myeloma patients. The study of 516 patients showed 68.6% vs 69.0% survival rates at seven years, with indefinite treatment associated with higher toxicity and second primary cancer incidence. Results suggest fixed-duration maintenance could become the new standard of care.

07/15/2026, 5:00 PM • GlobeNewswire

Autoimmune Disease Therapeutics Market Size to Reach USD 137.85 Billion by 2035 as Biologics and Precision Medicine Drive Growth | SNS Insider

The global autoimmune disease therapeutics market is projected to grow from USD 80.54 billion in 2025 to USD 137.85 billion by 2035, with a CAGR of 5.52%. Growth is driven by rising prevalence of autoimmune diseases, adoption of biologics, JAK inhibitors, monoclonal antibodies, and precision medicine technologies. North America leads with 39.96% market share, while Asia-Pacific shows the fastest growth at 6.28% CAGR.

07/15/2026, 11:00 AM • GlobeNewswire

Biotech ETFs: How Do FBT and IBB Match Up on Cost, Structure, and Performance?

First Trust NYSE Arca Biotechnology Index Fund (FBT) and iShares Biotechnology ETF (IBB) offer different approaches to biotech sector exposure. FBT uses a concentrated 30-stock portfolio with higher returns (53.2% one-year, 168% ten-year) but greater risk, while IBB provides broader diversification with 248 holdings and lower fees (0.44% vs 0.55%). FBT has outperformed IBB over the past decade despite higher concentration risk.

07/12/2026, 3:30 PM • The Motley Fool